Primary information |
---|
ID | antitb_1335, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | IC50 = <0.0125 μg/mL (50%) |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL male mice and male beagle dogs |
Mechanism of Action | 10 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1336, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium intracellulare |
In Vitro/ In vivo | Mycobacterium intracellulare |
Cell Line | IC50 = 1.56 μg/mL (50%) |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL male mice and male beagle dogs |
Mechanism of Action | 11 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1337, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium kansasii |
In Vitro/ In vivo | Mycobacterium kansasii |
Cell Line | IC50= 0.39 μg/mL (50%) |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL male mice and male beagle dogs |
Mechanism of Action | 12 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1338, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | IC90= 0.05 μg/mL(90%) |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL male mice and male beagle dogs |
Mechanism of Action | 13 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1339, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium intracellulare |
In Vitro/ In vivo | Mycobacterium intracellulare |
Cell Line | IC90= 0.78 μg/mL(90%) |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL male mice and male beagle dogs |
Mechanism of Action | 14 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1340, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium kansasii |
In Vitro/ In vivo | Mycobacterium kansasii |
Cell Line | IC90= 0.78 μg/mL(90%) |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL male mice and male beagle dogs |
Mechanism of Action | 15 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1341, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium bovis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL Mice |
Mechanism of Action | 15 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | 4mg of DHMPA peptide+ 0.1 mg of Isoniazid |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1342, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis R-KM |
Inhibition Concentration | Both |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | ICR/JCL Mice |
Mechanism of Action | 15 mg/kg for mice and 50mg/kg for dog |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | 4mg of DHMPA peptide+ 0.1 mg of Isoniazid |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1343, |
Name | 3348603 |
N-Terminal modification | Dihydromycoplanecin A |
C-Terminal Modification | R-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3) |
Chemical Modification | Propanol is attached |
Linear/Cyclic | Free |
Length | R =CH3-CH2-CH(OH)-CO |
Chirality | Cyclic |
Nature | 21 |
Source | Mix |
Species | Natural |
Strain | Aspergillus awajinensis |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | Mycobacterium smegmatis ATCC 607 |
Cell Line | FIC= 0.250 - 0.375 |
Sequence | 1988 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | DHMPA+ Isoniazid |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |